Literature DB >> 11380424

A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome.

S Gritli1, S Omar, E Tartaglini, S Guannouni, J C Fleming, M P Steinkamp, C I Berul, R Hafsia, S B Jilani, A Belhani, M Hamdi, E J Neufeld.   

Abstract

Thiamine-responsive megaloblastic anaemia (TRMA) syndrome with diabetes and deafness was found in two patients from a Tunisian kindred. The proband was homozygous for a novel mutation, 287delG, in the high-affinity thiamine transporter gene, SLC19A2. We demonstrated that fibroblasts from this patient exhibited defective thiamine transport. These data confirm that the SLC19A2 gene is the high-affinity thiamine carrier and that this novel mutation is responsible for TRMA syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11380424     DOI: 10.1046/j.1365-2141.2001.02774.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3.

Authors:  Wen-Qi Zeng; Eiman Al-Yamani; James S Acierno; Susan Slaugenhaupt; Tammy Gillis; Marcy E MacDonald; Pinar T Ozand; James F Gusella
Journal:  Am J Hum Genet       Date:  2005-05-03       Impact factor: 11.025

2.  Thiamine-responsive megaloblastic anemia: identification of novel compound heterozygotes and mutation update.

Authors:  Anke K Bergmann; Inderneel Sahai; Jill F Falcone; Judy Fleming; Adam Bagg; Caterina Borgna-Pignati; Robin Casey; Luca Fabris; Elizabeth Hexner; Lulu Mathews; Maria Leticia Ribeiro; Klaas J Wierenga; Ellis J Neufeld
Journal:  J Pediatr       Date:  2009-07-29       Impact factor: 4.406

Review 3.  Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome.

Authors:  A Lorber; A Z Gazit; A Khoury; Y Schwartz; H Mandel
Journal:  Pediatr Cardiol       Date:  2003 Sep-Oct       Impact factor: 1.655

4.  Genetics and genomic medicine in Tunisia.

Authors:  Houda Elloumi-Zghal; Habiba Chaabouni Bouhamed
Journal:  Mol Genet Genomic Med       Date:  2018-03       Impact factor: 2.183

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.